| アブストラクト | Treatment for multiple myeloma (MM) can involve apheresis to mobilize hematopoietic stem cells for later autologous stem cell transplantation (ASCT), which can become costly over time. This retrospective claims database study examined healthcare resource use and medical costs associated with plerixafor, a selective CXCR4 inhibitor that mobilizes hematopoietic stem cells and minimizes apheresis times. Medical data were sampled from Japanese MM patients between April 2017 and September 2019, after the Japanese launch of plerixafor. The study population (190 plerixafor users and 180 non-users) was identified from the Medical Data Vision database, and further stratified into those using granulocyte-colony stimulating factor in monotherapy or in combination with cyclophosphamide to trigger apheresis. A descriptive comparison of patient characteristics, healthcare resource use, and medical costs across the mobilization and ASCT phases indicated plerixafor is associated with higher average total medical costs. However, plerixafor-treated patients received fewer concomitant medications and spent less time in apheresis than non-users. A comparison of non-users with a similar analysis conducted pre-plerixafor launch (2013-2017) showed general improvements to treatment independent of plerixafor. The results of this research can inform guidelines for the role of plerixafor in balancing cost-effectiveness and drug efficacy in MM treatment. |
|---|
| ジャーナル名 | International journal of hematology |
|---|
| Pubmed追加日 | 2022/5/14 |
|---|
| 投稿者 | Iida, Shinsuke; Ishida, Tadao; Miyamoto, Toshihiro; Teramukai, Satoshi; Shirai, Heigoroh; Kanamori, Rie; Tajima, Yuki; Crawford, Bruce; Yi, Jingbo; Teshima, Takanori |
|---|
| 組織名 | Department of Hematology and Oncology, Nagoya City University Institute of;Medical and Pharmaceutical Sciences, Nagoya, Japan.;Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.;Department of Hematology, Faculty of Medicine, Institute of Medical;Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.;Department of Biostatistics, Graduate School of Medical Science, Kyoto;Prefectural University of Medicine, Kyoto, Japan.;Sanofi K. K., Tokyo, Japan.;Syneos Health, Tokyo, Japan.;Department of Hematology, Faculty of Medicine, Hokkaido University, Hokkaido,;Japan. teshima@med.hokudai.ac.jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35551631/ |
|---|
